The molecular and pathway changes that occur between primary carcinomas and metastases in the LAd Kras/Lkb1L/L model have been associated with the enrichment of GE signatures associated with the ESC phenotype, and the activation of epithelial-mesenchymal-transition (EMT), focal adhesion and oncogenic signalling (EGFR or ERBB2) [11]. The gene discussed is ERBB2; the disease is carcinoma.